Detection of fibrin generation alterations in dogs with haemangiosarcoma using resonance thrombography.
OBJECTIVE
The objective of the study was to examine the alterations of fibrin generation in dogs with haemangiosarcoma using resonance thrombography. The second objective was to evaluate the sensitivity of this method for the detection of hypofibrinogenaemia and/or increased fibrin(ogen) degradation product (FDP) concentration.


METHODS
Resonance thrombogram (RTG) measurements with two different instruments were performed in 30 unselected dogs with haemangiosarcoma, 14 of which had decreased fibrinogen and 28 of which had an increased FDP concentration (p<0.0001).


RESULTS
The RTG-reaction time was less sensitive than the fibrin formation time (RTG-f) and fibrin amplitude (RTG-F). The RTG-f and RTG-F indicated reliably a decrease in fibrinogen concentration (sensitivity: 0.93). The sensitivity of detection of increased FDP levels was considerably higher than that of thrombin time. However, false-negative results were found even at FDP concentrations > or =120 mg/l, especially in cases with high fibrinogen level. Both machines showed similar sensitivity.


CONCLUSIONS
The results of this study indicate that canine haemangiosarcoma is frequently associated with severe alterations of fibrin generation due to low fibrinogen and high FDP levels leading to distinct RTG abnormalities. The global test RTG reacts sensitively to a decreased fibrinogen level whereas its accuracy to detect FDP concentrations occurring under pathophysiological conditions is limited. A significant alteration of fibrin generation induced by FDPs may not occur until the serum FDP concentration exceeds 60 mg/l.
Mischke
R
R
Small Animal Clinic, Hannover School of Veterinary Medicine, Bischofsholer Damm 15, D-30173 Hannover, Germany.
Wohlsein
P
P
Schoon
H-A
HA
D000818:Animals; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests / Q000379:methods; D004285:Dogs; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism* / Q000494:pharmacology; D006394:Hemangiosarcoma / Q000662:veterinary*; D010976:Platelet Count; D012680:Sensitivity and Specificity
D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D005337:Fibrin